Pharmaceutical combinations comprising pyrido [1, 2-a] pyrimidone compounds and EGFR inhibitors

The invention belongs to the field of medical chemistry, and relates to a pharmaceutical composition comprising a pyrido [1, 2-a] pyrimidone compound and an EGFR inhibitor. Specifically, the pharmaceutical composition comprises a compound represented by a formula (I) or a pharmaceutically acceptable...

Full description

Saved in:
Bibliographic Details
Main Authors YU DING, WANG XUNQIANG, WU JIANGPENG, ZHANG CHURU, GUI ZAIZHI, FU ZHAOJIAN
Format Patent
LanguageChinese
English
Published 16.08.2024
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention belongs to the field of medical chemistry, and relates to a pharmaceutical composition comprising a pyrido [1, 2-a] pyrimidone compound and an EGFR inhibitor. Specifically, the pharmaceutical composition comprises a compound represented by a formula (I) or a pharmaceutically acceptable salt thereof and osimertinib or a pharmaceutically acceptable salt thereof, and an application of the pharmaceutical composition, or the compound represented by the formula (I) or the pharmaceutically acceptable salt thereof in treatment of non-small cell lung cancer independently. # imgabs0 # 本申请属于医药化学领域，涉及包括吡啶并[1，2-a]嘧啶酮化合物和EGFR抑制剂的药物组合。具体而言，其药物组合包括式(I)化合物或其药学上可接受的盐和奥希替尼或其药学上可接受的盐，以及该药物组合、或式(I)化合物或其药学上可接受的盐单独使用在治疗非小细胞肺癌中的用途。#imgabs0#
Bibliography:Application Number: CN20238015685